NCT00630045View on ClinicalTrials.gov

Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis

PHASE3UnknownINTERVENTIONAL
Enrollment

392

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2015

Conditions
Colorectal CancerResectable Liver Metastasis
Interventions
DRUG

neoadjuvant chemotherapy with oxaliplatin and capecitabine

oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)

PROCEDURE

resection of liver metastasis

surgery with the aim of R0 resection

Trial Locations (2)

100036

RECRUITING

Peking University, School of Oncology, Beijing

100044

RECRUITING

Peking University, People's Hospital, Beijing

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Peking University

OTHER

collaborator

Sanofi

INDUSTRY

lead

Peking University People's Hospital

OTHER